Calliditas: The Final Countdown - Redeye

Calliditas delivers a positive surprise in total sales, including royalty contributions from Asia, US patient enrollment (in line with our expectations), and new subscribers (15% above our expectations). The actual US sales growth during H1 is positive at >70%, which is reassuring, and it makes sense to measure H1 growth as Q1 was indirectly impacted by the cyberattack with some reversal during Q2. Calliditas enters H2 with a very positive momentum.

Länk till analysen i sin helhet: https://www.redeye.se/research/1030013/calliditas-update-the-final-countdown?utm_source=finwire&utm_medium=RSS